• Soliton Seeks 510 Clearance for its Generation II RAP Device

    7 days ago - By Surgical Aesthetics Magazine

    Soliton, a medical device company using a Rapid Acoustic Pulse platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, has filed for Special 510 Premarket Notification with the U.S. Food and Drug Administration for its Generation II RAP device.
    The Generation II RAP device is indicated for the same tattoo-removal therapy as the Generation I device, but is slightly modified for improved ease of use in the physician's office. Although, similar technology was utilized in the company's pivotal cellulite and proof of concept keloid scar trials, only...
    Read more ...